Lead Product(s) : Teicoplanin,Arbekacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
REYON's Teicoplanin and Arbekacin Enter Preclinical Trials for COVID-19
Details : Teicoplanin is a glycopeptide antibiotic, which is being evaluated in combination with arbekacin sulfate for the treatment of covid-19.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 06, 2020
Lead Product(s) : Teicoplanin,Arbekacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable